Low-dose IL-2 therapy limits the reduction in absolute numbers of peripheral lymphocytes in systemic lupus erythematosus patients with infection

References

• Kaul A, Gordon C, Crow MK, et al. Systemic lupus erythematosus. Nat Rev Dis Primers. J 2016;2:16039.
   PubMed Web of Science ®Google Scholar
• Fors Nieves CE, Izmirly PM. Mortality in systemic lupus erythematosus: an updated review. Curr Rheumatol Rep. 2016;18(4):21.
   PubMed Web of Science ®Google Scholar
• Pan Q, Liu Z, Liao S, et al. Current mechanistic insights into the role of infection in systemic lupus erythematosus. Biomed Pharmacother. 2019;117:109122.
   PubMed Web of Science ®Google Scholar
• Kedves M, Kosa F, Kunovszki P, et al. Large-scale mortality gap between SLE and control population is associated with increased infection-related mortality in lupus. Rheumatology. 2020;59(11):3443–3451.
   PubMed Web of Science ®Google Scholar
• Bouza E, Moya JG, Munoz P. Infections in systemic lupus erythematosus and rheumatoid arthritis. Infect Dis Clin North Am. 2001;15(2):335–361.
   PubMed Web of Science ®Google Scholar
• Rua-Figueroa I, Lopez-Longo J, Galindo-Izquierdo M, et al. Incidence, associated factors and clinical impact of severe infections in a large, multicentric cohort of patients with systemic lupus erythematosus. Semin Arthritis Rheum. 2017;47(1):38–45.
   PubMed Web of Science ®Google Scholar
• Wang J, Niu R, Jiang L, et al. The diagnostic values of C-reactive protein and procalcitonin in identifying systemic lupus erythematosus infection and disease activity. Medicine. 2019;98(33):e16798.
   PubMed Web of Science ®Google Scholar
• Dorner T, Jacobi AM, Lee J, et al. Abnormalities of B cell subsets in patients with systemic lupus erythematosus. J Immunol Methods. 2011;363(2):187–197.
   PubMed Web of Science ®Google Scholar
• Becker AM, Dao KH, Han BK, et al. SLE peripheral blood B cell, T cell and myeloid cell transcriptomes display unique profiles and each subset contributes to the interferon signature. PLOS One. 2013;8(6):e67003.
   PubMed Web of Science ®Google Scholar
• Abud-Mendoza C, Cuevas-Orta E, Santillan-Guerrero EN, et al. Decreased blood levels of B lymphocytes and NK cells in patients with systemic lupus erythematosus (SLE) infected with papillomavirus (HPV). Arch Dermatol Res. 2013;305(2):117–123.
   PubMed Web of Science ®Google Scholar
• Ferreira VdS, Mesquita FV, Mesquita DJ, et al. The effects of freeze/thawing on the function and phenotype of CD4(+) lymphocyte subsets in normal individuals and patients with systemic lupus erythematosus. Cryobiology. 2015;71(3):507–510.
   PubMed Web of Science ®Google Scholar
• Doaty S, Agrawal H, Bauer E, et al. Infection and lupus: which causes which? Curr Rheumatol Rep. 2016;18(3):13.
   PubMed Web of Science ®Google Scholar
• Levashov PA, Sedov SA, Belogurova NG, et al. Bacteriolytic activity of human interleukin-2. Biochemistry. 2012;77(11):1312–1314.
   PubMed Web of Science ®Google Scholar
• Arenas-Ramirez N, Woytschak J, Boyman O. Interleukin-2: biology, design and application. Trends Immunol. 2015;36(12):763–777.
   PubMed Web of Science ®Google Scholar
• Siegel JP, Rook AH, Djeu JY, et al. Interleukin 2 therapy in infectious diseases: rationale and prospects. Infection. 1985;13(Suppl 2):S219–S223.
   PubMed Web of Science ®Google Scholar
• He J, Zhang X, Wei Y, et al. Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus. Nat Med. 2016;22(9):991–993.
   PubMed Web of Science ®Google Scholar
• Ballesteros-Tato A, Papillion A. Mechanisms of action of low-dose IL-2 restoration therapies in SLE. Curr Opin Immunol. 2019;61:39–45.
   PubMed Web of Science ®Google Scholar
• He J, Zhang R, Shao M, et al. Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2020;79(1):141–149.
   PubMed Web of Science ®Google Scholar
• Zhao C, Chu Y, Liang Z, et al. Low dose of IL-2 combined with rapamycin restores and maintains the long-term balance of Th17/treg cells in refractory SLE patients. BMC Immunol. 2019;20(1):32.
   PubMed Web of Science ®Google Scholar
• Dulic S, Vasarhelyi Z, Sava F, et al. T-Cell subsets in rheumatoid arthritis patients on long-term anti-TNF or IL-6 receptor blocker therapy. Mediators Inflamm. 2017;2017:6894374.
   PubMed Web of Science ®Google Scholar
• Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725.
   PubMed Web of Science ®Google Scholar
• Thomas G, Mancini J, Jourde-Chiche N, et al. Mortality associated with systemic lupus erythematosus in France assessed by multiple-cause-of-death analysis. Arth Rheumatol. 2014;66(9):2503–2511.
   PubMed Web of Science ®Google Scholar
• Goldblatt F, Chambers S, Rahman A, et al. Serious infections in British patients with systemic lupus erythematosus: hospitalisations and mortality. Lupus. 2009;18(8):682–689.
   PubMed Web of Science ®Google Scholar
• Petri M, Genovese M. Incidence of and risk factors for hospitalizations in systemic lupus erythematosus: a prospective study of the Hopkins lupus cohort. J Rheumatol. 1992;19(10):1559–1565.
   PubMed Web of Science ®Google Scholar
• Edwards CJ, Lian TY, Badsha H, et al. Hospitalization of individuals with systemic lupus erythematosus: characteristics and predictors of outcome. Lupus. 2003;12(9):672–676.
   PubMed Web of Science ®Google Scholar
• Tektonidou MG, Wang Z, Dasgupta A, et al. Burden of serious infections in adults with systemic lupus erythematosus: a national population-based study, 1996–2011. Arthritis Care Res. 2015;67(8):1078–1085.
   Web of Science ®Google Scholar
• Iliopoulos AG, Tsokos GC. Immunopathogenesis and spectrum of infections in systemic lupus erythematosus. Semin Arthritis Rheum. 1996;25(5):318–336.
   PubMed Web of Science ®Google Scholar
• Noël V, Lortholary O, Casassus P, et al. Risk factors and prognostic influence of infection in a single cohort of 87 adults with systemic lupus erythematosus. Ann Rheum Dis. 2001;60(12):1141–1144.
   PubMed Web of Science ®Google Scholar
• Cervera R, Khamashta MA, Font J, et al. Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1,000 patients. European working party on systemic lupus erythematosus. Medicine. 1999;78(3):167–175.
   PubMed Web of Science ®Google Scholar
• Jacobsen S, Petersen J, Ullman S, et al. A multicentre study of 513 Danish patients with systemic lupus erythematosus. II. Disease mortality and clinical factors of prognostic value. Clin Rheumatol. 1998;17(6):478–484.
   PubMed Web of Science ®Google Scholar
• Halberg P, Alsbjorn B, Balslev JT, et al. Systemic lupus erythematosus. Follow-up study of 148 patients. II: predictive factors of importance for course and outcome. Clin Rheumatol. 1987;6(1):22–26.
   PubMed Web of Science ®Google Scholar
• Hernández-Cruz B, Tapia N, Villa-Romero AR, et al. Risk factors associated with mortality in systemic lupus erythematosus. A case-control study in a tertiary care center in Mexico City. Clin Exp Rheumatol. 2001;19(4):395–401.
   PubMed Web of Science ®Google Scholar
• Jung JY, Suh CH. Infection in systemic lupus erythematosus, similarities, and differences with lupus flare. Korean J Intern Med. 2017;32(3):429–438.
   PubMed Web of Science ®Google Scholar
• Feldman CH, Hiraki LT, Winkelmayer WC, et al. Serious infections among adult medicaid beneficiaries with systemic lupus erythematosus and lupus nephritis. Arthritis Rheumatol. 2015;67(6):1577–1585.
   PubMed Web of Science ®Google Scholar
• Lisnevskaia L, Murphy G, Isenberg D. Systemic lupus erythematosus. Lancet. 2014;384(9957):1878–1888.
   PubMed Web of Science ®Google Scholar
• Kim HA, Jung JY, Suh CH. Usefulness of neutrophil-to-lymphocyte ratio as a biomarker for diagnosing infections in patients with systemic lupus erythematosus. Clin Rheumatol. 2017;36(11):2479–2485.
   PubMed Web of Science ®Google Scholar
• Li Z, Xiao Y, Zhang L. Application of procalcitonin, white blood cell count and neutrophil-to-lymphocyte ratio in the diagnosis of systemic lupus erythematosus with a bacterial infection. Ann Palliat Med. 2020;9(6):3870–3876.
   PubMed Web of Science ®Google Scholar
• Wu L, Wang X, Chen F, et al. T cell subsets and immunoglobulin G levels are associated with the infection status of systemic lupus erythematosus patients. Braz J Med Biol Res. 2017;51(2):e4547.
   PubMed Web of Science ®Google Scholar
• Sturrock RD. Hematologic disorders in rheumatic disease. Curr Opin Rheumatol. 1991;3(1):172.
   PubMedGoogle Scholar
• Lazarus AH, Ellis J, Semple JW, et al. Comparison of platelet immunity in patients with SLE and with ITP. Transfus Sci. 2000;22(1-2):19–27.
   PubMedGoogle Scholar
• Guo Q, Ma XX, Gao H, et al. Association of semaphorin 3A with thrombocytopenia in systemic lupus erythematosus. Beijing Da Xue Xue Bao Yi Xue Ban. 2020;52(5):892–896.
   PubMedGoogle Scholar
• Yang F, Tian J, Peng L, et al. Thrombocytopenia is an independent risk factor for the prognosis of thrombotic microangiopathy in Chinese patients with systemic lupus erythematosus. Front Med. 2021;8:772607.
   Web of Science ®Google Scholar
• Boyman O, Sprent J. The role of interleukin-2 during homeostasis and activation of the immune system. Nat Rev Immunol. 2012;12(3):180–190.
   PubMed Web of Science ®Google Scholar
• Miyasaka N, Nakamura T, Russell IJ, et al. Interleukin 2 deficiencies in rheumatoid arthritis and systemic lupus erythematosus. Clin Immunol Immunopathol. 1984;31(1):109–117.
   PubMedGoogle Scholar
• Klatzmann D, Abbas AK. The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases. Nat Rev Immunol. 2015;15(5):283–294.
   PubMed Web of Science ®Google Scholar
• Bayer AL, Yu A, Adeegbe D, et al. Essential role for interleukin-2 for CD4(+)CD25(+) T regulatory cell development during the neonatal period. J Exp Med. 2005;201(5):769–777.
   PubMed Web of Science ®Google Scholar
• Nihei J, Cardillo F, Mengel J. The blockade of interleukin-2 during the acute phase of Trypanosoma cruzi infection reveals its dominant regulatory role. Front Cell Infect Microbiol. 2021;11:758273.
   PubMed Web of Science ®Google Scholar
• Bayer AL, Pugliese A, Malek TR. The IL-2/IL-2R system: from basic science to therapeutic applications to enhance immune regulation. Immunol Res. 2013;57(1–3):197–209.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA. IL-2: the first effective immunotherapy for human cancer. J Immunol. 2014;192(12):5451–5458.
   PubMed Web of Science ®Google Scholar
• Wang D, Fu B, Shen X, et al. Restoration of HBV-specific CD8(+) T-cell responses by sequential low-dose IL-2 treatment in non-responder patients after IFN-alpha therapy. Signal Transduct Target Ther. 2021;6(1):376.
   PubMed Web of Science ®Google Scholar
• Zwirner NW, Domaica CI. Cytokine regulation of natural killer cell effector functions. Biofactors. 2010;36(4):274–288.
   PubMed Web of Science ®Google Scholar
• Littwitz-Salomon E, Dittmer U, Sutter K. Insufficient natural killer cell responses against retroviruses: how to improve NK cell killing of retrovirus-infected cells. Retrovirology. 2016;13(1):77.
   PubMed Web of Science ®Google Scholar
• Kang I, Park SH. Infectious complications in SLE after immunosuppressive therapies. Curr Opin Rheumatol. 2003;15(5):528–534.
   PubMed Web of Science ®Google Scholar
• Saadoun D, Rosenzwajg M, Joly F, et al. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med. 2011;365(22):2067–2077.
   PubMed Web of Science ®Google Scholar
• Zhang R, Xi X, Wang C, et al. Therapeutic effects of recombinant human interleukin 2 as adjunctive immunotherapy against tuberculosis: a systematic review and meta-analysis. PLOS One. 2018;13(7):e0201025.
   PubMed Web of Science ®Google Scholar
• Levashov PA, Ovchinnikova ED, Morozova OA, et al. Human interleukin-2 and hen egg white lysozyme: screening for bacteriolytic activity against various bacterial cells. Acta Naturae. 2016;8(1):98–102.
   PubMed Web of Science ®Google Scholar
• Levashov PA, Matolygina DA, Ovchinnikova ED, et al. Bacteriolytic activity of human interleukin-2, chicken egg lysozyme in the presence of potential effectors. Acta Naturae. 2017;9(2):82–87.
   PubMed Web of Science ®Google Scholar
• Zhou P, Chen J, He J, et al. Low-dose IL-2 therapy invigorates CD8+ T cells for viral control in systemic lupus erythematosus. PLoS Pathog. 2021;17(10):e1009858.
   PubMed Web of Science ®Google Scholar